Johnson & Johnson Reports 77% Tumor Response Rate in Head and Neck Cancer Trial

04:35 AM EDT, 10/26/2026 (MT Newswires) -- Johnson & Johnson (JNJ) said late Sunday that its investigational Rybrevant Faspro combination achieved a 77% confirmed response rate in a phase 1b/2 study of patients with recurrent or metastatic head and neck cancer, excluding HPV-associated oropharyngeal cancer. The regimen achieved complete responses in 14% of the 22 patients, with 65% of responses ongoing at a median follow-up of 10.6 months. The median time to response was 9.4 weeks, and the one-year survival rate was 77%, the company said. The findings support further evaluation in the ongoing phase 3 OrigAMI-5 study. The most common side effects included anemia, low albumin levels, reduced platelet counts and mouth inflammation. Johnson & Johnson said an application for Rybrevant Faspro in later-line head and neck cancer is under Priority Review with the US Food and Drug Administration.